Efficacy of 3% hypertonic saline in bronchiolitis: A meta-analysis

Area of Science:

• Pediatrics
• Pulmonology
• Evidence-Based Medicine

Background:

• Bronchiolitis is a common viral respiratory infection in infants.
• Current treatments primarily focus on supportive care.
• The efficacy of hypertonic saline (HS) as a therapeutic agent requires further evaluation.

Purpose of the Study:

• To conduct a meta-analysis evaluating the effectiveness of 3% hypertonic saline (HS) in treating infants diagnosed with bronchiolitis.
• To compare HS treatment with standard normal saline (NS) therapy.

Main Methods:

• A systematic search of PubMed and MEDLINE databases was conducted.
• Two authors independently selected studies based on predefined inclusion criteria.
• Data extraction and meta-analysis were performed using weighted mean difference (WMD) and relative risk (RR) with 95% confidence intervals (CI).

Main Results:

• Infants treated with 3% HS showed significantly shorter hospital stays (WMD=-0.43; 95% CI=-0.70, -0.15) compared to NS.
• A subgroup analysis indicated that 3% HS combined with epinephrine further reduced hospital stay (WMD=-0.62; 95% CI=-0.90, -0.33).
• A lower clinical severity score (CSS) was observed in the 3% HS group (SMD=-0.80; 95% CI=-1.06, -0.54).
• No significant difference in re-admission rates was found (RR=0.93; 95% CI=0.70, 1.23).

Conclusions:

• 3% hypertonic saline (HS) is a more effective therapy than normal saline (NS) for infants with bronchiolitis.
• HS treatment leads to reduced hospitalization duration and improved clinical severity.
• Further research may explore optimal HS combination therapies.